We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Novel RT-PCR Test Enables Early Detection of Parkinson’s Disease

By LabMedica International staff writers
Posted on 29 Sep 2023

Parkinson's disease (PD) is a neurological disorder with no known definitive cause, although it is thought that both genetics and environmental factors play a role. More...

There is currently no cure for the disease. When patients begin to show typical signs of PD, a significant loss of dopamine-producing cells has already occurred, making it difficult to halt further brain decline. As the disease advances, problems with movement and speech arise, affecting the individual's independence. For these reasons, genetic testing becomes vital for assessing an individual's risk and for early detection. Identifying specific genetic mutations linked to PD not only helps people make educated healthcare choices but also guides researchers in developing targeted treatments. Understanding these genetic factors can further contribute to personalized treatment strategies, improving patient care.

In the search for early detection methods for PD, accurately identifying the condition has proven to be challenging. Anbio Biotechnology (Frankfurt, Germany) has developed a promising approach using real-time polymerase chain reaction (RT-PCR) technology for early PD detection. Studies have found that early-onset PD is commonly associated with mutations in the GBA and LRRK2 genes. Among these mutations, L444P, G2385R, and R1628P are notably prevalent. To address this, Anbio has introduced its GBA L444P/LRRK2 R1628P/LRRK2 G2385R Gene Mutations Polymorphism Test Kit. This RT-PCR assay is specifically designed to rapidly and accurately identify these three key genetic polymorphisms in the GBA and LRRK2 genes.

The kit employs a highly specialized Taq enzyme and fluorescent probes to enhance detection specificity. Quality control is maintained through the use of internal and multiple positive controls, reducing the chances of false negatives and positives. The test can identify these three specific GBA and LRRK2 genetic polymorphisms in as little as 117 minutes. The procedure is straightforward, and the test results are easy to understand, objective, and reliable. When it comes to accuracy, sensitivity, and specificity, the kit outperforms other similar products available on the market. The findings generated by Anbio's test kit are significant not only for understanding the mechanisms behind PD but also for shaping effective treatment strategies.

Related Links:
Anbio Biotechnology 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Microbiology

view channel
Image: Development of targeted therapeutics and diagnostics for extrapulmonary tuberculosis at University Hospital Cologne (Photo courtesy of Michael Wodak/Uniklinik Köln)

Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis

Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. Despite TB infecting 10 million people yearly, the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.